#Japan #Tokyo #Medical Device #InMode #Mophius Pro

InMode Japan's New Medical Device Approval

InMode Japan, a subsidiary of InMode Ltd., which distributes medical devices to over 100 countries worldwide, has made significant advancements in the field of aesthetic medicine. As of October 3, 2025, the company has announced that it has received manufacturing and sales approval for its latest device, the Mophius Pro. This device aims to improve skin aesthetics through fractional resurfacing techniques, specifically targeting the vaporization of soft tissues.

Product Overview

The Mophius Pro is categorized as a Class III medical device, recognized for its high-level management and specific maintenance requirements. The device has been assigned the approval number 30700BZX00257000 and is poised to serve as a groundbreaking tool in dermatological treatments.

Purpose and Effectiveness

The device's primary indication is for fractional skin resurfacing, which ultimately enhances the aesthetic appearance of the skin. Its function focuses on the vaporization of soft tissues, providing effective treatment for various skin imperfections, enhancing overall skin quality, and offering patients a non-invasive option for skincare.

The Technology Behind Mophius Pro

Mophius Pro utilizes advanced energy-based technology that allows for customized treatment options tailored to individual patient needs. One of the key benefits of this device is its ability to promote healing while delivering noticeable results with minimal downtime. This positions Mophius Pro as a preferred choice for both practitioners and patients in the aesthetics industry.

About InMode Japan

InMode Japan, established in July 2023, is located in the heart of Tokyo at VORT Kyobashi III, 9th Floor, 2-6-17 Kyobashi, Chuo Ward, Tokyo. The company is led by Kazuhiko Iwashita, its executive director. InMode Japan is committed to providing innovative medical technology that ensures quality treatments and contributes to the beauty and wellness of individuals.

Market Implications

The introduction of the Mophius Pro in the Japanese market addresses a growing demand for non-surgical aesthetic procedures. Healthcare professionals specializing in dermatology and cosmetic surgery are increasingly looking for technologically advanced devices that can enhance patient satisfaction while maintaining safety and efficiency. The approval of Mophius Pro is expected to significantly impact the dermatological sector, offering a competitive alternative in aesthetic treatments.

Conclusion

In summary, the Mophius Pro represents a pivotal moment in the aesthetic medical device industry, combining technological innovation with patient-centered treatment approaches. With its recent approval, InMode Japan is set to lead the way in providing effective solutions for skin rejuvenation and aesthetic enhancements, remaining dedicated to its mission of improving patient outcomes and satisfaction.